Since patients with NAFLD have decreased hepatic expression of protein and mRNA of FXR and it is associated with hepatic steatosis, inflammation, fibrosis, injury, and even cancer [80], FXR appears to gain increasing interest as a promising target to treat NAFLD. The gene discussed is NR1H4; the disease is fatty liver disease.